



# Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants

Adam Cuker, MD, MS,\* Deborah M. Siegal, MD, MSc,† Mark A. Crowther, MD, MSc,† David A. Garcia, MD‡

## ABSTRACT

**BACKGROUND** Non-vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in special situations and populations.

**OBJECTIVES** This study's objective was to systematically review and summarize current evidence regarding laboratory measurement of the anticoagulant activity of dabigatran, rivaroxaban, and apixaban.

**METHODS** We searched PubMed and Web of Science for studies that reported a relationship between drug levels of dabigatran, rivaroxaban, and apixaban and coagulation assay results. Study quality was evaluated using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2).

**RESULTS** We identified 17 eligible studies for dabigatran, 15 for rivaroxaban, and 4 for apixaban. For dabigatran, a normal thrombin time excludes clinically relevant drug concentrations. The activated partial thromboplastin time (APTT) and prothrombin time (PT) are less sensitive and may be normal at trough drug levels. The dilute thrombin time ( $R^2 = 0.92$  to  $0.99$ ) and ecarin-based assays ( $R^2 = 0.92$  to  $1.00$ ) show excellent linearity across on-therapy drug concentrations and may be used for drug quantification. For rivaroxaban and apixaban, anti-Xa activity is linear ( $R^2 = 0.89$  to  $1.00$ ) over a wide range of drug levels and may be used for drug quantification. Undetectable anti-Xa activity likely excludes clinically relevant drug concentrations. The PT is less sensitive (especially for apixaban); a normal PT may not exclude clinically relevant levels. The APTT demonstrates insufficient sensitivity and linearity for quantification.

**CONCLUSIONS** Dabigatran, rivaroxaban, and apixaban exhibit variable effects on coagulation assays. Understanding these effects facilitates interpretation of test results in NOAC-treated patients. More information on the relationship between drug levels and clinical outcomes is needed. (J Am Coll Cardiol 2014;64:1128-39) © 2014 by the American College of Cardiology Foundation.

**D**abigatran etexilate, an oral prodrug of the direct thrombin inhibitor dabigatran, and the oral direct inhibitors of factor Xa, rivaroxaban and apixaban, are approved in the United States, Europe, and Canada to prevent stroke and

systemic embolism in patients with nonvalvular atrial fibrillation (AF). They are also variably licensed for treatment of venous thromboembolism (VTE) and prevention of VTE after major orthopedic surgery (MOS) in certain jurisdictions. We refer to these

From the \*Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; †Department of Medicine, McMaster University, Hamilton, Ontario, Canada; and the ‡Department of Medicine, University of Washington, Seattle, Washington. This work was supported by grant HL112903 (National Heart, Lung, and Blood Institute) to Dr. Cuker. Dr. Cuker has served as a consultant for Baxter, Bayer, and Genzyme; has served on advisory boards for Daiichi Sankyo and Genzyme; and has received research support from Diagnostica Stago. Dr. Crowther has served on advisory boards for and/or received consulting fees from Boehringer Ingelheim, Portola, Viropharm, and AKP America; has received research funding from Leo Pharma (McMaster University); and has received funding for presentations from Bayer, Celgene, Shire, and CSL Behring. Dr. Garcia has served as a consultant to Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, Daiichi Sankyo, Pfizer, and Roche. Dr. Siegal has reported that she has no relationships relevant to the contents of this paper to disclose.

Manuscript received January 13, 2014; revised manuscript received May 21, 2014, accepted May 26, 2014.



agents collectively as non-vitamin K oral anticoagulants (NOACs) in this paper. Synonymous terms preferred by other researchers include direct-acting oral anticoagulant agents and new, novel, or target-specific oral anticoagulant agents (1).

Unlike warfarin and other vitamin K antagonists (VKAs), the NOACs are administered in fixed doses and do not require routine laboratory monitoring (2-4). However, measurement of their anticoagulant activity may be desirable in special clinical settings such as bleeding; the pre-operative state; breakthrough thrombosis; and suspected overdose, noncompliance, or drug interactions and in certain populations, including those with extremes in body weight and in the elderly and patients with renal insufficiency in whom there is a risk of drug accumulation. Assessment of anticoagulant effect may also be important in patients with AF presenting with acute ischemic stroke before administration of thrombolytic therapy (5).

SEE PAGE 1140

Numerous studies on use of coagulation assays for measurement of NOAC activity have been published recently, although a systematic review has not been undertaken. The objective of our analysis was to summarize current evidence regarding laboratory measurement of NOAC anticoagulant activity and to provide evidence-based guidance to practicing cardiologists on the interpretation of coagulation tests in NOAC-treated patients.

## METHODS

**LITERATURE SEARCH.** We performed a systematic review of the literature to examine current evidence for laboratory measurement of the NOACs. A search of PubMed and Web of Science from inception through December 1, 2013, was undertaken separately for dabigatran, rivaroxaban, and apixaban using the following key words: "name of drug" AND ((laboratory measurement) OR (laboratory monitoring)).

**STUDY SELECTION.** Articles were examined, first by title and abstract and then by review of the complete paper as indicated. Additional articles were sought by reviewing bibliographies. Liquid chromatography/tandem mass spectrometry (LC-MS/MS) is the reference method for measurement of the plasma concentration of NOACs (6). Studies that reported the relationship between drug (or active metabolite) levels in human plasma, as measured directly using LC-MS/MS or indirectly using LC-MS/MS-validated

calibration standards and 1 or more clinical coagulation assays, were eligible for inclusion. We excluded animal studies, abstracts only, and non-English language publications.

**DATA EXTRACTION.** We extracted key characteristics from eligible studies and recorded them in an evidence table. These included author, year of publication, setting, NOAC (i.e., dabigatran, rivaroxaban, or apixaban), reference method for measurement of drug levels, range of drug concentrations studied, test material (i.e., ex vivo patient plasma, ex vivo healthy control plasma, or spiked normal plasma), dose (for studies using ex vivo plasma only), indication (for studies using ex vivo patient plasma only), number of samples (for studies using individual [i.e., unpooled] plasma only), coagulation assays and reagents, and descriptors of the relationship between drug level and coagulation assay (e.g.,  $R^2$  values, range of linearity).

**QUALITY ASSESSMENT.** Study quality was evaluated using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2), a standardized tool for quality assessment of studies of diagnostic accuracy. The tool comprises 4 domains: patient selection, index test, reference standard, and flow and timing. Risk of bias is assessed across all domains; the first 3 domains are also assessed with respect to applicability to clinical practice (7).

## RESULTS

**DABIGATRAN.** Dabigatran etexilate, an oral non-peptide prodrug, is rapidly converted to the active drug dabigatran by ubiquitous esterases. Dabigatran directly inhibits both free and clot-bound thrombin. It has relatively poor bioavailability (approximately 6.5%) and is eliminated predominantly by the kidneys (80%). In individuals with normal renal function, the half-life of dabigatran is 12 to 14 h. Prolonged clearance and bioaccumulation are observed in patients with renal insufficiency (8). In patients with non-valvular AF and normal kidney function, the dose is 150 mg twice daily, which is reduced in patients with renal insufficiency.

Peak levels of dabigatran occur 2 to 3 h after ingestion. Steady-state peak and trough concentrations in patients with AF and normal renal function taking dabigatran 150 mg twice daily are shown in Table 1 (8). Substantial interindividual variability in drug exposure is observed. In the PETRO (Prevention of Embolic and Thrombotic Events in Patients

## ABBREVIATIONS AND ACRONYMS

ACT	= activated clotting time
AF	= atrial fibrillation
APTT	= activated partial thromboplastin time
ECA	= ecarin chromogenic assay
ECT	= ecarin clotting time
NOAC	= non-vitamin K oral anticoagulant
PICT	= prothrombinase-induced clotting time
POC	= point of care
PT/INR	= prothrombin time/international normalized ratio
TT	= thrombin time
VKA	= vitamin K antagonist

**TABLE 1** Expected Steady-State Peak and Trough Concentrations of Dabigatran, Rivaroxaban, and Apixaban Derived From Pharmacokinetic Studies

Drug	Dose	Study Population	Peak, ng/ml	Trough, ng/ml	Ref. #
Dabigatran	150 mg bid	Patients with AF	184*	90*	(9,10)
Rivaroxaban	20 mg qd	Patients with AF	274†	30†	(33)
Apixaban	5 mg bid	Healthy male volunteers	129‡	50‡	(52)


Only standard doses approved for AF are shown. \*Median. †Median estimated by mathematical modeling. ‡Mean.

AF = atrial fibrillation; bid = twice daily; qd = once daily.

With Persistent Atrial Fibrillation) study, the range (5th to 95th percentile) in peak and trough concentrations in patients taking 150 mg twice daily was 64 to 443 ng/ml and 31 to 225 ng/ml, respectively (9,10).

**Study selection.** Our literature search yielded 160 articles. Nine additional references were identified from bibliographies. A total of 152 articles were excluded: 135 did not report an original research study, 14 did not report drug levels measured by LC-MS/MS, and 3 were published as abstracts only. The remaining 17 articles (11-27) met eligibility criteria (Figure 1). Eligible studies were collectively conducted in 9 different countries across a range of dabigatran concentrations from 0 to 1,886 ng/ml. Only 4 studies used ex vivo plasma from dabigatran-treated patients; the remainder involved ex vivo healthy volunteer plasma or normal plasma spiked in vitro with dabigatran as the test material (Table 2).

**Activated partial thromboplastin time.** Twelve eligible studies reported a relationship between the activated partial thromboplastin time (APTT) and dabigatran levels. Three used ex vivo patient



**TABLE 2** Characteristics of Eligible Dabigatran Studies

Ref. #	Setting	Range of Drug Concentrations, ng/ml	Test Material	Indication (n)	Dose, mg	Coagulation Test		R <sup>2</sup>
						APTT	ECT	
(10)	Germany	NR	Ex vivo patient plasma	MOS (287)	12.5-300 bid; 150-300 qd	APTT	NR	NR
(11)	Germany	NR	Ex vivo healthy volunteer plasma	NA (80)	10-400 SD; 50-400 tid	APTT	0.85	
						ECT	0.92-0.96	
						PT/INR	0.83-0.85	
						TT	0.60-0.86	
(12)	Germany	NR	Ex vivo healthy volunteer plasma	NA (35)	150 bid	APTT	NR	
(13)	Sweden	0-1,000	Spiked normal pooled plasma	NA (NA)	NA	APTT	NR	
(14)	United States	0-500	Spiked normal pooled plasma	NA (NA)	NA	APTT	0.95*	
						Dilute TT	0.98	
						TT	NR	
(15)	United States, United Kingdom, Canada	25-500	Spiked normal pooled plasma	NA (NA)	NA	APTT	0.96	
						PT/INR	0.99	
						TT	NR	
(16)	Belgium	4.7-943	Spiked normal pooled plasma	NA (NA)	NA	APTT	0.96-0.99	
						Dilute PT	NR	
						Dilute TT	0.99	
						ECA	0.99	
						ECT	1.00	
						PICT	NR	
						PT/INR	NR	
						TT	NR	
(17)	Austria	0-480	Spiked normal pooled plasma	NA (NA)	NA	APTT	NR	
(18)	Germany	0-1,000	Spiked normal pooled plasma	NA (NA)	NA	APTT	NR	
						ECT	NR	
						PT/INR	NR	
(19)	New Zealand	30-960	Spiked normal pooled plasma	NA (NA)	NA	Dilute TT	NR	
(20)	Germany	0-1,886	Spiked normal pooled plasma	NA (NA)	NA	Dilute TT	0.99	
(21)	Germany	50-1,400	Spiked healthy volunteer plasma	NA (4)	NA	POC-INR	NR	
						PT/INR	NR	
(22)	Sweden	<0.5-586	Ex vivo patient plasma	AF (70)	NR	APTT	0.58	
						Dilute TT	0.97	
						ECA	0.96	
						PT/INR	0.48	
(23)	United States	0-500	Ex vivo patient plasma Spiked normal pooled plasma	AF (NR) VTE (NR) NA (NA)	150 bid NA	Dilute TT	0.96-0.97	
						ECA	0.99	
(24)	United States	18-487	Ex vivo patient plasma	AF (29) VTE (6)	NR	ACT	0.71	
						APTT	0.74-0.82	
						Dilute TT	0.92	
						ECA	0.94-0.99	
						ECT	0.98	
						PT/INR	0.60-0.86	
						TT	0.75-0.97	
(25)	Sweden	0-985.5	Spiked normal pooled plasma	NA (NA)	NA	PT/INR	NR	
(26)	Finland	120-300	Spiked normal pooled plasma	NA (NA)	NA	APTT	NR	
						PT/INR	NR	
						TT	NR	

\*Relationship described by second-order polynomial regression.

ACT = activated clotting time; APTT = activated partial thromboplastin time; ECA = ecarin chromogenic assay; ECT = ecarin clotting time; INR = international normalized ratio; MOS = major orthopedic surgery; NA = not applicable; NR = not reported; PICT = prothrombinase-induced clotting time; POC = point of care; PT = prothrombin time; SD = single dose; tid = 3 times daily; TT = thrombin time; VTE = venous thromboembolism; other abbreviations as in Table 1.

plasma, 2 ex vivo healthy volunteer plasma, and 7 normal plasma spiked with dabigatran in vitro (Table 2). Dabigatran prolonged the APTT in a concentration-dependent manner in both ex vivo and in vitro studies. The dose response was linear

up to a concentration of 200 to 300 ng/ml and then flattened out at higher drug levels (17,28). This curvilinear relationship did not permit quantitative assessment of dabigatran levels, particularly at higher concentrations.

Commercial APTT reagents differ widely in their sensitivity to dabigatran. The APTT of plasma spiked with dabigatran 120 ng/ml ranged from 26.0 to 91.9 s in a cross-validation study of 9 different APTT methods (27). These findings suggest that coagulation laboratories should perform dose-response studies using calibration standards to determine the sensitivity of their particular APTT method to dabigatran and communicate the results to clinicians. The least sensitive reagents required a dabigatran concentration of approximately 400 ng/ml to produce a 2-fold prolongation in the APTT over control (19). The APTT may not be prolonged in the presence of typical on-therapy trough levels (Table 1), particularly if a relatively insensitive reagent is used. In a study of ex vivo plasma from patients taking dabigatran 150 mg twice daily, 18% of participants had a normal APTT at trough (25). In another study of patients with AF, some samples had an APTT within the normal range despite dabigatran concentrations as high as 60 ng/ml (23).

**Prothrombin time/international normalized ratio.** Eleven studies reported a relationship between dabigatran levels and the prothrombin time/international normalized ratio (PT/INR). Eight used spiked plasma, 2 ex vivo patient plasma, and 1 ex vivo plasma from healthy volunteers (Table 2). Dabigatran prolonged the PT in a concentration-dependent manner, as defined by an exponential (i.e., non-linear) relationship (17). The PT/INR was less sensitive to dabigatran than the APTT. In an ex vivo study of patients with AF, an INR of 1.2 or greater was only observed with dabigatran concentrations in excess of 400 ng/ml (23).

As with APTT, commercial PT reagents differ in their sensitivity to dabigatran. In a survey of 71 coagulation laboratories, the PT of plasma spiked to a concentration of 300 ng/ml ranged from 15.7 to 50.2 s, depending on the reagent (27). PT may be measured using 2 assay types. The Quick method is influenced by the entire extrinsic and common pathways of coagulation, whereas the Owren method is affected only by factors II, VII, and X. In studies of spiked plasma, Quick PT reagents were more sensitive to dabigatran than Owren reagents (14,27).

Point-of-care devices are available for measuring the INR (POC-INR) in whole blood in VKA-treated patients. In one study assessing the relationship between dabigatran levels and a single POC-INR system, the POC system yielded INR values 2- to 4-fold higher than those obtained using a laboratory PT/INR method. Dabigatran concentrations >500 ng/ml were beyond the POC system's limit of detection (22).

**Thrombin time.** Six studies reported a relationship between thrombin time (TT) and dabigatran levels (Table 2). The TT (in unmodified form) was inordinately sensitive in both ex vivo and in vitro studies. Depending on the reagent, dabigatran concentrations of as little as 25 and up to 150 ng/ml exceeded the limits of detection (15-17,28).

**Dilute TT.** In the dilute TT assay, the excessive sensitivity of the TT is overcome by diluting the plasma sample (21). Seven studies reported a relationship between the dilute TT and dabigatran concentration (Table 2). Two studies used an in-house modification of the TT (15,20); 5 used the HEMOCLOT thrombin inhibitor assay (HYPHEN BioMed, Neuville-sur-Oise, France), a commercially available dilute TT test (17,21,23-25). Dabigatran prolonged the assay in a concentration-dependent manner. The relationship showed a high degree of linearity, with  $R^2$  values ranging between 0.92 and 0.99 in both in vitro and ex vivo studies. The lower limit of detection according to the manufacturer is 50 ng/ml (21). Two studies determined the assay to be less accurate and more variable at concentrations below 50 to 100 ng/ml (15,21). The dilute TT is currently not widely available; in a recent survey in Australia and New Zealand, only 9 of 592 laboratories reported using it (29).

**Ecarin-based assays.** Ecarin is a snake venom that cleaves prothrombin to form meizothrombin, an unstable intermediate of thrombin. Dabigatran inhibits the thrombin-like activity of meizothrombin (24). Two assays use ecarin as an activator: the ecarin clotting time (ECT) and ecarin chromogenic assay (ECA).

Six studies reported a relationship between ECT and dabigatran levels (Table 2). Both in vitro and ex vivo studies demonstrated a high degree of linearity, with  $R^2$  values ranging between 0.92 and 1.00. Loss of linearity was observed in 2 studies at dabigatran levels in excess of 470 to 500 ng/ml (17,19). A relationship between ECA and drug levels was reported in 4 studies (Table 2). The relationship was linear, with  $R^2$  values of 0.94 to 0.99 in in vitro and ex vivo samples. One study identified greater variability at dabigatran concentrations <50 ng/ml (23). The ECT and ECA are hampered by lack of standardization, variability in sensitivity to dabigatran among different lots of ecarin, and limited availability (17,20).

**Other assays.** Relationships between dabigatran level and the dilute PT, prothrombinase-induced clotting time (PiCT), and activated clotting time (ACT) were each reported in a single study. Both the dilute PT and PiCT evinced a complex nonlinear dose-response curve (17). As with heparin, the ACT

proved insensitive to lower concentrations of dabigatran. In an ex vivo study, the ACT was normal in 40% of trough samples despite on-therapy dabigatran levels (25).

**RIVAROXABAN.** Rivaroxaban is an oral inhibitor of free and clot-associated factor Xa through reversible, competitive interactions with its active site (30). Bioavailability following oral administration is dose dependent (80% to 100% following a 10-mg dose; 66% following a 20-mg dose). It is highly bound to plasma proteins (>90%) (31); plasma levels peak 2 to 4 h following oral administration (32,33). Partially excreted by the kidneys (36%), rivaroxaban has a half-life of 6 to 13 h depending on dose and age (31-35). Table 1 shows expected peak and trough plasma concentrations in patients with AF treated with 20 mg daily (36).

**Study selection.** Our literature search yielded 134 unique rivaroxaban articles. Two additional

references were identified from bibliographies. We excluded 121 articles: 108 did not report an original research study, 12 did not report a relationship between a coagulation assay and drug levels measured by LC-MS/MS, and 1 was published as an abstract only. The remaining 15 articles (27,37-50) met eligibility criteria (Figure 1). Rivaroxaban concentrations in eligible studies ranged from 0 to >1,000 ng/ml. Four studies used ex vivo plasma from rivaroxaban-treated patients, 1 incorporated ex vivo plasma from healthy controls, and the remainder used normal plasma spiked in vitro with rivaroxaban (Table 3).

**Prothrombin time.** We found 11 studies evaluating the effect of rivaroxaban on PT (Table 3). In general, rivaroxaban prolonged the PT in a concentration-dependent, linear fashion in plasma spiked with rivaroxaban and in plasma from patients receiving rivaroxaban for approved indications. On-therapy rivaroxaban concentrations showed a modest effect

**TABLE 3** Characteristics of Eligible Rivaroxaban Studies

Ref. #	Setting	Range of Drug Concentration, ng/ml	Test Material	Indication (n)	Dose, mg	Coagulation Test	R <sup>2</sup>
(26)	Europe	60-305	Spiked normal pooled plasma	NA (NA)	NA	Anti-Xa APTT PT/INR	NR NR NR
(36)	United States, Canada	<10->1,000	Spiked normal pooled plasma	NA (NA)	NA	PT/INR	NR
(37)	France	0-1,000	Spiked normal pooled plasma	NA (NA)	NA	Anti-Xa APTT Dilute PT Dilute RVVT PiCT POC-INR PT/INR	NR 0.90-0.98 0.97-0.99 0.99 NR 1.00 0.99-1.00
(38)	France	NR	Ex vivo patient plasma	MOS (166)	10 qd	Anti-Xa APTT PT/INR	0.97-1.00 0.75 0.47
(39)	Germany	25-900	Spiked normal pooled plasma	NA (NA)	NA	Anti-Xa	NR
(40)	Sweden	0-1,000	Spiked normal pooled plasma	NA (NA)	NA	Anti-Xa APTT PT/INR	NR NR NR
(41)	Italy	100-700	Spiked normal pooled plasma	NA (NA)	NA	PT/INR	NR
(42)	Switzerland	40-150	Ex vivo healthy volunteer plasma Spiked normal pooled plasma	NA (20) NA (NA)	10 qd NA	Anti-Xa	0.98-0.99
(43)	Germany	1.9-283.0	Ex vivo patient plasma	MOS (80)	10 qd	Anti-Xa	1.00
(44)	the Netherlands	0-1,000	Spiked normal pooled plasma	NA (NA)	NA	Anti-Xa APTT PT/INR	NR 1.00 1.00*
(45)	Europe, North America	20-662	Spiked normal pooled plasma	NA (NA)	NA	Anti-Xa	NR
(46)	Europe, North America	19-643	Spiked normal pooled plasma	NA (NA)	NA	PT/INR	NR
(47)	the Netherlands	0-800	Spiked normal pooled plasma	NA (NA)	NA	PT/INR	1.00
(48)	Belgium	NR	Ex vivo patient plasma	AF, VTE (52)	NR	Anti-Xa PT/INR	0.95 0.58-0.66
(49)	France	NR	Ex vivo patient plasma	MOS (41)	10 qd	Anti-Xa PT/INR	0.99 NR

\*Relationship described by second-order polynomial regression.

RVVT = Russell viper venom time; other abbreviations as in Tables 1 and 2.

**TABLE 4** Characteristics of Eligible Apixaban Studies

Ref. #	Setting	Range of Drug Concentration, ng/ml	Test Material	Indication (n)	Dose, mg	Coagulation Test	R <sup>2</sup>
(36)	United States, Canada	<10->1,000	Ex vivo patient plasma Spiked normal pooled plasma	VTE (348) NA (NA)	5-10 bid, 20 qd NA	Anti-Xa PT/INR	0.88-0.89 0.36
(53)	Global	1-933	Ex vivo patient plasma	ACS (1,691)	5-20 qd	Anti-Xa	0.97
(54)	United States	0-2,500	Ex vivo healthy volunteer plasma Spiked healthy volunteer plasma	NA (39) NA (21)	20 SD NA	PT/INR	0.41
(55)	France	0-1,000	Spiked normal pooled plasma	NA (NA)	NA	Anti-Xa APTT PT/INR	NR NR NR

ACS = acute coronary syndrome; other abbreviations as in Tables 1 and 2.

on PT. Typical trough (41 to 60 ng/ml) and peak (219 to 305 ng/ml) concentrations increased PT by 6% to 19% and 50% to 135%, respectively (27,38,42,47). Assay sensitivity varied significantly among thromboplastin reagents. Interassay variability was reduced by use of an international sensitivity index specific for rivaroxaban but not by conversion to an INR used for monitoring VKA therapy (38,42). These observations suggest that coagulation laboratories should perform dose-response studies using calibration standards to determine the sensitivity of their particular PT method for rivaroxaban and communicate the results to clinicians.

**Activated partial thromboplastin time.** Five studies evaluated the effect of rivaroxaban on APTT (Table 3). Whereas rivaroxaban prolonged APTT in a dose-dependent manner, the overall relationship between rivaroxaban concentration and APTT prolongation was nonlinear, with studies reporting conflicting data regarding the concentration ranges over which nonlinearity was most pronounced (27,41,45). Similar to PT results, there was significant variability among reagents and among individual laboratories in a multicenter study (27,45). Hillarp *et al.* (41) reported that the APTT assay was insensitive at the lowest drug level studied (25 ng/ml).

**Anti-Xa activity.** Ten studies assessed the effect of rivaroxaban on anti-Xa activity (Table 3). In general, the studies showed a linear, concentration-dependent relationship between rivaroxaban concentration and anti-Xa activity over a wide range of concentrations (e.g., 20 to 660 ng/ml) when they were measured using a standard curve generated with rivaroxaban calibrators and controls with R<sup>2</sup> values ranging from 0.95 to 1.00 (39,43,44,49,50). The correlation was less robust at concentrations <100 ng/ml (49). However, Samama *et al.* (46) demonstrated that low rivaroxaban concentrations could be measured with a modified anti-Xa test using less diluted

samples. Investigators found a greater degree of assay imprecision at higher rivaroxaban concentrations (800 ng/ml) in one study (45). In a multicenter study, both intralaboratory and interlaboratory precision were satisfactory except at the lower limit of detection (20 ng/ml); use of a centrally distributed reagent reduced interlaboratory variability (46). Mathematical modeling also decreased interassay variability resulting from different sensitivities of individual reagents to rivaroxaban (40). When commercial anti-Xa assays were used with unfractionated or low-molecular-weight heparin (LMWH) calibrators (rather than rivaroxaban calibrators), the relationship remained linear up to a rivaroxaban concentration of 500 ng/ml (38,41).

**Other assays.** The relationship between rivaroxaban concentration and the dilute PT, dilute Russell viper venom time (dRVVT), and PiCT was evaluated in a single study (38). Researchers uncovered a linear, dose-dependent relationship between rivaroxaban and the dilute PT. Rivaroxaban increased the dRVVT ratio (expressed as ratio vs. baseline) in a concentration-dependent but nonlinear manner. At low concentrations of rivaroxaban (<200 ng/ml), there was a paradoxical shortening of PiCT, whereas PiCT was prolonged in a concentration-dependent fashion at higher concentrations.

**APIXABAN.** Like rivaroxaban, apixaban is a small, orally available, direct inhibitor of coagulation factor Xa (51). It has 50% bioavailability and, in healthy volunteers, reaches its maximum plasma concentration approximately 3 h after ingestion. Apixaban is highly protein bound in plasma, and concomitant food intake has little impact on its pharmacokinetics (52). Metabolized through multiple routes, apixaban is less dependent on renal clearance than dabigatran and rivaroxaban. In persons with normal renal function, apixaban has a half-life of approximately 12 h (53). As measured by LC-MS/MS, the expected

steady-state concentrations of apixaban have been published by Frost et al. (52) and are shown in **Table 1**.

**Study selection.** Our literature search for apixaban yielded 70 articles; 3 additional references were identified from bibliographies. Sixty-nine articles were excluded: 68 did not report an original research study and 1 was published as an abstract only. The remaining 4 articles (37,54-56) met eligibility criteria (**Figure 1**). Eligible studies collectively evaluated apixaban across a range of concentrations from 0 to 2,500 ng/ml (**Table 4**).

**Prothrombin time/international normalized ratio.** We found 3 studies that reported the relationship between the PT and apixaban levels. One study used both spiked normal plasma and ex vivo plasma from apixaban-treated patients (37), another used spiked plasma as well as ex vivo plasma from healthy volunteers taking apixaban (55), and the third study included only spiked normal plasma samples (56) (**Table 4**). For the 2 studies that used ex vivo plasma, the relationship was linear in one (37) and curvilinear in the other (55). Correlation was modest, with  $R^2$  values of 0.36 and 0.41, respectively. Across in vitro and ex vivo samples and for a variety of reagents, the PT was inadequately sensitive to apixaban, not only below, but also above the expected trough concentration of 50 ng/ml.

**Activated partial thromboplastin time.** Only 1 study compared apixaban concentrations with APTT (**Table 3**), which was measured using 10 different APTT reagents in normal plasma samples spiked with 10 different concentrations of apixaban. The sensitivity of the APTT was unacceptably low; all assays yielded a ratio of 1.1 times control when the spiked apixaban concentration was 100 ng/ml (i.e., twice the expected trough concentration).

**Anti-Xa activity.** Three studies compared anti-Xa activity measurements with the plasma concentration of apixaban (**Table 4**). In 2 of the studies (37,54), ex vivo patient samples were used, whereas the third study (56) included only spiked samples of normal plasma. In general, the relationship was linear at all apixaban concentrations, with  $R^2$  values ranging from 0.89 to 0.97. Available evidence suggests that an anti-Xa assay calibrated with LMWH standards will also correlate linearly with apixaban concentrations (37,54).

**STUDY QUALITY.** Assessment of study quality using QUADAS-2 criteria (7) highlighted several recurrent methodological concerns among eligible studies (**Table 5**). Many studies used in vitro samples or ex vivo samples from healthy controls rather than

ex vivo patient samples. Concern about the applicability of these studies to clinical practice within the patient selection domain was judged to be high. Some studies examined assays not widely available to clinicians (e.g., ECA, ECT, dilute TT). Concern regarding applicability of these studies to clinical practice across the index test domain was judged to be high. Because data correlating plasma NOAC levels and clinical outcomes are scarce, concern about the

**TABLE 5** Study Quality Assessment Using QUADAS-2 Criteria

Ref. #	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
<b>Dabigatran studies</b>							
(10)	L	U	U	L	L	H	H
(11)	NA	U	U	L	H	H	H
(12)	NA	U	U	L	H	H	H
(13)	NA	U	L	L	H	L	H
(14)	NA	U	L	L	H	H	H
(15)	NA	L	L	L	H	L	H
(16)	NA	U	L	L	H	H	H
(17)	NA	U	L	L	H	L	H
(18)	NA	U	L	L	H	H	H
(19)	NA	U	L	L	H	H	H
(20)	NA	U	L	L	H	H	H
(21)	NA	U	L	L	H	L	H
(22)	U	U	U	L	L	H	H
(23)	U	U	U	L	L	H	H
(24)	U	U	U	L	L	H	H
(25)	NA	U	L	L	H	L	H
(26)	NA	U	L	L	H	L	H
<b>Rivaroxaban studies</b>							
(26)	NA	U	U	L	H	L	H
(36)	NA	U	U	L	L	L	H
(37)	NA	U	L	L	H	H	H
(38)	U	U	U	L	L	L	H
(39)	NA	U	L	L	H	L	H
(40)	NA	U	L	L	H	L	H
(41)	NA	U	L	L	H	L	H
(42)	NA	L	L	L	H	L	H
(43)	U	U	U	L	L	L	H
(44)	NA	U	L	L	H	L	H
(45)	NA	L	L	L	H	L	H
(46)	NA	L	L	L	H	L	H
(47)	NA	U	L	L	H	L	H
(48)	U	U	U	L	L	L	H
(49)	U	U	U	L	L	L	H
<b>Apixaban studies</b>							
(36)	L	U	U	L	L	L	H
(53)	L	U	U	L	H	L	H
(54)	NA	U	U	L	H	L	H
(55)	NA	L	L	L	H	L	H

H = high; L = low; QUADAS-2 = Quality Assessment of Diagnostic Accuracy Studies 2; U = unclear; other abbreviations as in **Table 2**.

applicability of the reference standard (plasma drug concentration) to clinical practice was judged to be high for all eligible studies.

## DISCUSSION


This systematic review sought to examine evidence for laboratory measurement of the anticoagulant activity of dabigatran, rivaroxaban, and apixaban. Although data on the relationship between plasma NOAC levels and clinical outcomes are beginning to emerge (57), there is, as yet, no evidence that routine monitoring or dose titration will improve outcomes. Nevertheless, measurement may be useful in 3 circumstances: 1) to determine if very high levels are present (in the case of suspected excess effect [e.g., due to overdose or bioaccumulation]); 2) to determine if drug is present in typical on-therapy ranges (e.g., in the case of suspected therapeutic failure); and 3) to determine if any clinically relevant drug effect is present (e.g., in the case of bleeding or planned invasive procedures). An ideal assay would thus show adequate linearity, sensitivity, and reproducibility to enable quantification

across a broad range of drug levels. Apart from LC-MS/MS, a test generally restricted to select reference laboratories, no single coagulation assay meets these idealized standards. Therefore, it is important for clinicians to be aware of how coagulation tests perform at NOAC concentrations below, within, and above typical on-therapy ranges (**Central Illustration**).

**DABIGATRAN.** The effect of dabigatran on various coagulation assays is summarized in the **Central Illustration**. The TT is exquisitely sensitive to dabigatran. A normal TT excludes the presence of clinically relevant drug levels; however, the assay is too sensitive for quantification within and above the on-therapy range. The dilute TT, ECT, and ECA show a high degree of linearity at drug levels >50 ng/ml and are thus useful for quantification across the entire on-therapy range. They may be unreliable at concentrations below this threshold. The APTT is relatively insensitive to dabigatran; a normal APTT may not exclude clinically relevant below or within on-therapy drug levels. The curvilinear response of APTT at higher drug levels does not permit accurate quantification. The PT has even poorer sensitivity and may be normal within much of the on-therapy range.

**RIVAROXABAN.** Anti-Xa activity measured using chromogenic substrates and rivaroxaban or heparin/LMWH calibrators correlates linearly with rivaroxaban over a wide range of concentrations (20 to 660 ng/ml) (**Central Illustration**). When rivaroxaban calibrators are used, anti-Xa assays can provide a quantitative measure of rivaroxaban concentration. A negative anti-Xa assay likely excludes clinically relevant rivaroxaban levels. Although rivaroxaban prolongs the PT, assay results vary markedly with different thromboplastin reagents. A normal PT does not rule out the presence of clinically significant below or within on-therapy rivaroxaban concentrations; however, a prolonged PT qualitatively indicates the drug's presence. The APTT is not suitable for measuring rivaroxaban due to the nonlinear relationship with rivaroxaban concentration, poor sensitivity, and significant variability between reagents.

**APIXABAN.** Although both the PT and APTT may be prolonged in the presence of apixaban, neither is sufficiently sensitive to exclude the presence of clinically relevant on-therapy drug concentrations (**Central Illustration**). Anti-Xa activity measurements demonstrate a strong linear correlation with apixaban concentration; the absence of detectable anti-Xa



**CENTRAL ILLUSTRATION** Sensitivity and Linearity of Coagulation Assays to Below, Within, and Above Typical On-Therapy Concentrations of Dabigatran, Rivaroxaban, and Apixaban

Horizontal bars and vertical hatching correspond to the approximate range of detectability (i.e., sensitivity) and linearity, respectively, of each assay to below, within, and above typical on-therapy concentrations of dabigatran, rivaroxaban, and apixaban. Ranges are approximations and may vary on the basis of choice of reagent. Typical on-therapy drug levels are shown in **Table 1**. APTT = activated partial thromboplastin time; ECA = ecarin chromogenic assay; ECT = ecarin clotting time; PT = prothrombin time; TT = thrombin time.

**TABLE 6** Suggestions for Laboratory Measurement of Non-Vitamin K Oral Anticoagulants

Drug	Clinical Objective					
	Determine If Clinically Relevant Below On-Therapy Drug Levels Are Present		Estimate Drug Levels Within On-Therapy Range		Determine If Above On-Therapy Drug Levels Are Present	
	Suggested Test	Interpretation	Suggested Test	Interpretation	Suggested Test	Interpretation
Dabigatran	TT	Normal TT likely excludes clinically relevant drug levels	Dilute TT, ECA, ECT	—	APTT, dilute TT, ECA, ECT	Normal APTT likely excludes excess drug levels; only dilute TT, ECA, and ECT are suitable for quantitation
Rivaroxaban	Anti-Xa	Normal anti-Xa activity likely excludes clinically relevant drug levels	Anti-Xa	—	Anti-Xa, PT	Normal PT likely excludes excess drug levels; only anti-Xa is suitable for quantitation
Apixaban	Anti-Xa	Normal anti-Xa activity likely excludes clinically relevant drug levels	Anti-Xa	—	Anti-Xa	—

Suggestions for laboratory measurement of the anticoagulant activity of dabigatran, rivaroxaban, and apixaban are based on the clinical objective. Typical on-therapy drug levels are shown in Table 1. Abbreviations as in Table 2.

activity (whether the standard curve is established with apixaban or LMWH) likely excludes the presence of physiologically important apixaban activity.

**SUGGESTIONS AND COMPARISONS WITH GUIDANCE DOCUMENTS.** Recommendations for laboratory measurement of the NOACs differ by drug and clinical objective. The findings of our systematic review support the suggestions summarized in Table 6. These suggestions align with recommendations provided in drug labels and published guidance documents, with 2 notable exceptions. First, we found strong evidence from studies of ex vivo patient samples that a normal APTT does not definitively exclude on-therapy dabigatran concentrations (23,25). This observation is at variance with guidelines from the American Society of Hematology (ASH) and the British Committee for Standards in Haematology (BCSH), which state that a normal APTT is likely to exclude therapeutic intensity dabigatran (58) or contribution of dabigatran to bleeding (59). Second, we found that a normal PT does not exclude clinically relevant rivaroxaban levels. The BCSH statement, in contrast, comments that a normal PT ratio with most reagents excludes therapeutic intensity rivaroxaban (58). The ASH and BCSH statements were published in 2011 and 2012, respectively. Discrepancies between our findings and these statements may reflect availability of new information since their publication regarding a wider variety of test reagents and their sensitivity to the NOACs.

**STUDY LIMITATIONS.** Quality assessment highlighted several key limitations of eligible studies (Table 5). First, on-therapy ranges (Table 1) were

derived from pharmacokinetic analyses. We resisted the term “therapeutic range” because data on how these ranges correlate with clinical outcomes are sparse, although they are beginning to emerge (57). Second, many eligible studies used either ex vivo or spiked plasma samples from healthy controls rather than ex vivo samples from NOAC-treated patients. Reassuringly, results obtained with patient samples generally aligned with those from healthy controls. Third, we identified only 4 eligible apixaban studies, just 2 of which used ex vivo patient samples. Because apixaban was the most recent NOAC to receive regulatory approval, we expect that additional studies of its laboratory measurement will be forthcoming. Such studies are also needed for NOACs not yet approved in North America and Europe (e.g., edoxaban).

## CONCLUSIONS

A relatively large number of published studies have assessed the relationship between coagulation tests and levels of dabigatran, rivaroxaban, and apixaban. Each drug produces unique effects on coagulation assays. Our systematic review provides guidance to the clinician on how to use and interpret coagulation test results in NOAC-treated patients. Further studies are needed to define the relationship between drug levels, coagulation test results, and clinical outcomes.

**REPRINT REQUESTS AND CORRESPONDENCE:** Dr. Adam Cuker, Hospital of the University of Pennsylvania, 3 Dulles, 3400 Spruce Street, Philadelphia, Pennsylvania 19014. E-mail: adam.cuker@uphs.upenn.edu.

## PERSPECTIVES

**COMPETENCY IN MEDICAL KNOWLEDGE 1:** Pro-thrombin time (PT) and activated partial thromboplastin time (APTT) do not show sufficient sensitivity or linearity for quantification of dabigatran, rivaroxaban, or apixaban. A normal PT and/or APTT may not exclude clinically relevant anticoagulant effects of these drugs.

**COMPETENCY IN MEDICAL KNOWLEDGE 2:** A normal thrombin time likely excludes clinically relevant plasma levels of the direct thrombin inhibitor dabigatran. Dilute thrombin time and ecarin-based assays may be used to measure dabigatran activity.

**COMPETENCY IN MEDICAL KNOWLEDGE 3:** An anti-Xa assay using drug-specific calibrators may be used to measure the activity of the factor Xa inhibitors rivaroxaban and apixaban.

**COMPETENCY IN PATIENT CARE:** The NOACs dabigatran, rivaroxaban, and apixaban do not require laboratory monitoring of coagulation during routine clinical use, but measurement of their anticoagulant effect may be desirable in certain circumstances.

**TRANSLATIONAL OUTLOOK:** Development of laboratory assays for measurement of the anticoagulant activity of these NOACs is a high priority. Ideally, these assays should be sufficiently sensitive to detect all clinically relevant drug concentrations, show linearity across a wide range of concentrations to permit quantification, and be reproducible and simple to perform at the point of care.

## REFERENCES

1. Husted S, De Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. *Thromb Haemost* 2014; 111:781-2.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139-51.
3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;365:883-91.
4. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981-92.
5. Tripodi A. The laboratory and the direct oral anticoagulants. *Blood* 2013;121:4032-5.
6. Eby C. Novel anticoagulants and laboratory testing. *Int J Lab Med* 2013;35:262-8.
7. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529-36.
8. Gross PL, Weitz JI. New antithrombotic drugs. *Clin Pharmacol Ther* 2009;86:139-46.
9. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). *Am J Cardiol* 2007;100:1419-26.
10. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. *Thromb Haemost* 2010;103:1116-27.
11. Liesenfeld KH, Schäfer HG, Trocóniz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. *Br J Clin Pharmacol* 2006;62:527-37.
12. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. *Br J Clin Pharmacol* 2007;64:292-303.
13. Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. *Clin Pharmacokinet* 2008;47:47-59.
14. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. *Thromb Haemost* 2011;105:371-8.
15. Avcilla ST, Ferrell C, Chandler WL, et al. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. *Am J Clin Pathol* 2012;137:572-4.
16. Dager WE, Gosselin RC, Kitchen S, et al. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, *in vitro* study. *Ann Pharmacother* 2012;46:1627-36.
17. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. *Thromb Haemost* 2012;107:985-97.
18. Halbmayer WM, Weigel G, Quehenberger P, et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. *Clin Chem Lab Med* 2012;50:1601-5.
19. Harenberg J, Giese C, Marx S, et al. Determination of dabigatran in human plasma samples. *Semin Thromb Hemost* 2012;38:16-22.
20. Jones SD, Eddy NS, Chan GT. Dabigatran: laboratory monitoring. *Pathology* 2012;44:578-80.
21. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. *Blood Coagul Fibrinolysis* 2012;23:138-43.
22. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. *Am J Med* 2012;125:417-20.
23. Antovic JP, Skeppholm M, Eintre J, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. *Eur J Clin Pharmacol* 2013;69:1875-81.
24. Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. *Ann Pharmacother* 2013;47:1635-40.
25. Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. *J Thromb Haemost* 2013;11:1493-502.
26. He S, Wallén H, Bark N, et al. In vitro studies using a global hemostasis assay to examine the anticoagulant effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. *J Thromb Thrombolysis* 2013;35:131-9.
27. Helin TA, Pakkanen A, Lassila R, et al. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. *Clin Chem* 2013;59:807-14.

- 28.** Hapgood G, Butler J, Malan E, et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. *Thromb Haemost* 2013;110:308-15.
- 29.** Favaloro EJ, Bonar R, Butler J, et al. Laboratory testing for the new oral anticoagulants: a review of current practice. *Pathology* 2013;45:435-7.
- 30.** Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct factor Xa inhibitor. *J Thromb Haemost* 2005;3:514-21.
- 31.** Xarelto Summary of Product Characteristics—EU. Available at: [http://www.xarelto.com/html/downloads/2013-07\\_SPC\\_June2013\\_F2\\_low.pdf](http://www.xarelto.com/html/downloads/2013-07_SPC_June2013_F2_low.pdf). Accessed August 17, 2013.
- 32.** Kubitz D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. *Clin Pharmacol Ther* 2005;78:412-21.
- 33.** Kubitz D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. *Eur J Clin Pharmacol* 2005;61:873-80.
- 34.** Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141:e445-88S.
- 35.** Weinz C, Schwarz T, Kubitz D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. *Drug Metab Dispos* 2009;37:1056-64.
- 36.** Mueck W, Lensing AW, Agnelli G, et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. *Clin Pharmacokinet* 2011;50:675-86.
- 37.** Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. *Thromb Haemost* 2010;104:1263-71.
- 38.** Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. *Thromb Haemost* 2010;103:815-25.
- 39.** Freyburger G, Macouillard G, Labrouche S, et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. *Thromb Res* 2011;127:457-65.
- 40.** Harenberg J, Kramer R, Giese C, et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. *J Thromb Thrombolysis* 2011;32:267-71.
- 41.** Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. *J Thromb Haemost* 2011;9:133-9.
- 42.** Tripodi A, Chantarangkul V, Guinet C, et al. The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. *J Thromb Haemost* 2011;9:226-8.
- 43.** Asmis LM, Alberio L, Angelillo-Scherrer A, et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. *Thromb Res* 2012;129:492-8.
- 44.** Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of anti-thrombin. *Thromb Haemost* 2012;108:191-8.
- 45.** Molenaar PJ, Dinkelaar J, Leyte A. Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. *Clin Chem Lab Med* 2012;50:1799-807.
- 46.** Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. *Thromb Haemost* 2012;107:379-87.
- 47.** Samama MM, Contant G, Spiro TE, et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. *Clin Appl Thromb Hemost* 2012;18:150-8.
- 48.** Dinkelaar J, Molenaar PJ, Ninivaggi M, et al. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban. *J Thromb Haemost* 2013;11:1111-8.
- 49.** Douxfils J, Tamignau A, Chatelain B, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. *Thromb Haemost* 2013;110:723-31.
- 50.** Samama MM, Guinet C, Le Flem L, et al. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. *J Thromb Thrombolysis* 2013;35:140-6.
- 51.** Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. *Clin Pharmacokinet* 2013;52:69-82.
- 52.** Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. *Br J Clin Pharmacol* 2013;76:776-86.
- 53.** Eliquis (apixaban). Package Insert. Princeton, NJ: Bristol-Myers Squibb Co.
- 54.** Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor. *J Thromb Thrombolysis* 2011;32:183-7.
- 55.** Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. *Clin Appl Thromb Hemost* 2013;19:522-8.
- 56.** Gouin-Thibault I, Flaujac C, Delavenne X, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. *Thromb Haemost* 2014;111:240-8.
- 57.** Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY trial. *J Am Coll Cardiol* 2014;63:321-8.
- 58.** Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. *Br J Haematol* 2012;159:427-9.
- 59.** Cushman M, Lim W, Zakai NA. American Society of Hematology 2011 Clinical Practice Guide on Anticoagulant Dosing and Management of Anticoagulant-Associated Bleeding Complications in Adults. Available at: <http://www.hematology.org/Clinicians/Guidelines-Quality/Quick-Ref/525.aspx>. Accessed January 9, 2014.

**KEY WORDS** apixaban, dabigatran, laboratory, monitoring, rivaroxaban